Comparative Pharmacology
Head-to-head clinical analysis: ANCEF IN PLASTIC CONTAINER versus CEFTAZIDIME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANCEF IN PLASTIC CONTAINER versus CEFTAZIDIME.
ANCEF IN PLASTIC CONTAINER vs CEFTAZIDIME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefazolin, a first-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking and autolytic enzyme inhibition.
Ceftazidime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has broad-spectrum activity against Gram-negative bacteria, including Pseudomonas aeruginosa.
1-2 g IV/IM every 8 hours. Maximum 12 g/day.
1-2 g IV every 8 hours
None Documented
None Documented
1.5-2 hours in adults with normal renal function; prolonged to 10-30 hours in ESRD (CrCl <10 mL/min); anephric patients up to 40 hours.
Clinical Note
moderateCeftazidime + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Ceftazidime."
Clinical Note
moderateCeftazidime + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ceftazidime."
Clinical Note
moderateWarfarin + Ceftazidime
"Warfarin may increase the anticoagulant activities of Ceftazidime."
Clinical Note
moderatePhenprocoumon + Ceftazidime
2 hours (range 1.2-2.2 h) in normal renal function; prolonged to 10-15 h in end-stage renal disease; requires dose adjustment.
Primarily renal (80-96% unchanged within 24 hours via glomerular filtration and tubular secretion); minimal biliary (<1%) and fecal (<1%).
Primarily renal: 80-90% excreted unchanged in urine via glomerular filtration; small amount (≈1%) biliary; ≤1% fecal.
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"Phenprocoumon may increase the anticoagulant activities of Ceftazidime."